ESMO highlights: KRAS G12C inhibitors

David Hong, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses highlights from the European Society for Medical Oncology (ESMO) 2022 on KRAS G12C inhibitors. Compelling data was presented at ESMO on the combination of KRAS G12C inhibitors with cetuximab plus adagrasib and panitumumab in colorectal cancer, which demonstrated the combination of a G12C inhibitor plus an EGFR antibody can lead to clinical benefit in patients with chemo-refractory colorectal cancer. Additionally, the Phase III CodeBreak 200 (NCT04303780) trial of the RAS G12C inhibitor, sotorasib, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) demonstrated a superior progression-free survival (PFS) and objective response rate (ORR) with sotorasib. This interview took place at Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.